RIGL vs. MACK, RGLS, VSTM, EBS, VNDA, XOMA, LXRX, IXHL, OMER, and GBIO
Should you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Merrimack Pharmaceuticals (MACK), Regulus Therapeutics (RGLS), Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), Incannex Healthcare (IXHL), Omeros (OMER), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Merrimack Pharmaceuticals (NASDAQ:MACK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Rigel Pharmaceuticals had 12 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 13 mentions for Rigel Pharmaceuticals and 1 mentions for Merrimack Pharmaceuticals. Merrimack Pharmaceuticals' average media sentiment score of 1.01 beat Rigel Pharmaceuticals' score of -0.18 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the news media.
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 28.9% of Merrimack Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to Rigel Pharmaceuticals' net margin of -21.47%. Rigel Pharmaceuticals' return on equity of 0.00% beat Merrimack Pharmaceuticals' return on equity.
Rigel Pharmaceuticals received 50 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. Likewise, 68.81% of users gave Rigel Pharmaceuticals an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.
Merrimack Pharmaceuticals has lower revenue, but higher earnings than Rigel Pharmaceuticals. Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Rigel Pharmaceuticals presently has a consensus price target of $5.81, indicating a potential upside of 478.36%. Given Rigel Pharmaceuticals' higher probable upside, analysts clearly believe Rigel Pharmaceuticals is more favorable than Merrimack Pharmaceuticals.
Rigel Pharmaceuticals has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Merrimack Pharmaceuticals has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Summary
Rigel Pharmaceuticals beats Merrimack Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Rigel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rigel Pharmaceuticals Competitors List
Related Companies and Tools
